Centogene N.V. (Nasdaq: CNTG), the essential life science partner
for data-driven answers in rare and neurodegenerative diseases,
today announced its conference schedule for March 2023. CENTOGENE
representatives will be attending events in Brazil, the U.S., Saudi
Arabia, Thailand, and the U.K. and will be available to discuss
Pharma, CRO, and Diagnostic collaboration opportunities. The
Company invites attendees to schedule one-on-one meetings in
advance.
Please see additional details below:
3rd Brazilian Congress
of Neurogenetics 2023
Dates: March
9-11, 2023
Location: Frei
Caneca Convention Center, São Paulo, Brazil
CENTOGENE’s
Presentations:
Title: Increased
diagnostic precision with insights from a rare disease
biodatabank
Speaker: Prof. Peter
Bauer, CENTOGENE's Chief Medical & Genomic Officer
When: Friday, March
10, 2023, 8:30 a.m. – 8:55 a.m. BRT
Where: Room Turquesa
2
Title: Multiomics: A
new era of rare disease diagnostics
Speaker: Prof. Peter
Bauer, CENTOGENE's Chief Medical & Genomic Officer
When: Friday, March
10, 2023, 3:00 p.m. – 3:35 p.m. BRT
Where: Room Turquesa
1
Title: ROUNDTABLE -
My personal view on the future of neurogenetics in the next 5-10
years
Speaker: Prof. Peter
Bauer, CENTOGENE's Chief Medical & Genomic Officer
When: Saturday,
March 11, 2023, 3:50 p.m. – 5:05 p.m. BRT
Where: Room Turquesa
1 and 2
To learn more about the
3rd Brazilian Congress of Neurogenetics 2023 and set up an
in-person meeting with the CENTOGENE team, please visit the event
webpage (https://link.centogene.com/3KK0jgi).
American College of Medical Genetics & Genomics
(ACMG) Annual Clinical Genetics Meeting
Dates: March
14-18, 2023
Location: Salt
Palace Convention Center, Salt Lake City, U.S.
CENTOGENE’s Poster
Presentations:
Title: Beyond
genomics: Using RNA-seq in filter cards to unlock the clinical
relevance
Speaker: Jorge Pinto
Basto, Senior Medical Director at CENTOGENE
When: Thursday,
March 16, 2023, from 10:30 a.m. – 12:00 p.m. MDT
Where: Exhibit Hall
(Abstract #P427)
Title: Impact of
processed pseudogene insertions in genetic testing as cause of
monogenic diseases: Insertion in CLCN1 gene causing myotonia
congenita
Speaker: Jorge Pinto
Basto, Senior Medical Director at CENTOGENE
When: Friday, March
17, 2023, from 10:30 a.m. – 12:00 p.m. MDT
Where: Exhibit Hall
(Abstract #P576)
For information about the ACMG Annual
Clinical Genetics Meeting and to arrange a one-on-one meeting,
please refer to the event webpage
(https://link.centogene.com/3ENsNC2).
World Rare Disease Day Conference 2023
Dates: March
15-16, 2023
Location: King
Salman Abdul Aziz Medical City, Medina, Saudi Arabia
To learn more about the World Rare
Disease Day Conference 2023 and set up an in-person meeting with
the CENTOGENE team, please visit the event webpage
(https://link.centogene.com/41ujRvn).
6th Annual Gene
Therapy for Rare Disorders 2023 Summit
Dates: March
20-23, 2023
Location: Sheraton
Boston Hotel, Boston, U.S.
For information about the 6th Annual
Gene Therapy for Rare Disorders 2023 Summit and to arrange a
one-on-one meeting, please refer to the event webpage
(https://link.centogene.com/3KLIzRP).
The 6th Asian Congress
on Inherited Metabolic Diseases 2023
Dates: March
22-24, 2023
Location: Arnoma
Grand Bangkok, Bangkok, Thailand
To learn more about the 6th Asian
Congress on Inherited Metabolic Diseases 2023 and set up an
in-person meeting with the CENTOGENE team, please visit the event
webpage (https://link.centogene.com/3ZpRrRe).
Pharma USA 2023
Dates: March
28-29, 2023
Location:
Pennsylvania Convention Center, Philadelphia, U.S.
For information about Pharma USA 2023
and to arrange a one-on-one meeting, please refer to the event
webpage (https://link.centogene.com/3yfvHvO).
Research & Innovation 2023 Meeting
Dates: March
29-30, 2023
Location: Hinxton Hall Conference Centre,
Hinxton, U.K.
CENTOGENE’s
Presentations:
Title: Using patient
data to enable drug discovery in rare diseases
Speaker: Guido
Hartmann, VP Global Head Research and Development at CENTOGENE
When: Wednesday,
March 29, 2023, 11:10 a.m. BST
Where: Rosalind
Franklin Room
To learn more about the European
Laboratory Research & Innovation Group’s (ELRIG) Research &
Innovation 2023 conference and set up an in-person meeting with the
CENTOGENE team, please visit the event webpage
(https://link.centogene.com/3YKdpOh).
About CENTOGENE
CENTOGENE’s mission is to provide data-driven, life-changing
answers to patients, physicians, and pharma companies for rare and
neurodegenerative diseases. We integrate multiomic technologies
with the CENTOGENE Biodatabank – providing dimensional analysis to
guide the next generation of precision medicine. Our unique
approach enables rapid and reliable diagnosis for patients,
supports a more precise physician understanding of disease states,
and accelerates and de-risks targeted pharma drug discovery,
development, and commercialization.
Since our founding in 2006, CENTOGENE has been offering rapid
and reliable diagnosis – building a network of approximately 30,000
active physicians. Our ISO, CAP, and CLIA certified multiomic
reference laboratories in Germany utilize Phenomic, Genomic,
Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets.
This data is captured in our CENTOGENE Biodatabank, with nearly
700,000 patients represented from over 120 highly diverse
countries, over 70% of whom are of non-European descent. To date,
the CENTOGENE Biodatabank has contributed to generating novel
insights for more than 260 peer-reviewed publications.
By translating our data and expertise into tangible insights, we
have supported over 50 collaborations with pharma partners.
Together, we accelerate and de-risk drug discovery, development,
and commercialization in target and drug screening, clinical
development, market access and expansion, as well as offering the
CENTOGENE Biodatabank Licenses and Insight Reports to enable a
world healed of all rare and neurodegenerative diseases.
To discover more about our products, pipeline, and
patient-driven purpose, visit www.centogene.com and follow us on
LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” are
generally intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause
CENTOGENE’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward- looking
statements. Such risks and uncertainties include, among others,
negative economic and geopolitical conditions and instability and
volatility in the worldwide financial markets, possible changes in
current and proposed legislation, regulations and governmental
policies, pressures from increasing competition and consolidation
in our industry, the expense and uncertainty of regulatory
approval, including from the U.S. Food and Drug Administration, our
reliance on third parties and collaboration partners, including our
ability to manage growth, execute our business strategy and enter
into new client relationships, our dependency on the rare disease
industry, our ability to manage international expansion, our
reliance on key personnel, our reliance on intellectual property
protection, fluctuations of our operating results due to the effect
of exchange rates, our ability to streamline cash usage, our
continued ongoing compliance with covenants linked to financial
instruments, our requirement for additional financing, or other
factors. For further information on the risks and uncertainties
that could cause actual results to differ from those expressed in
these forward-looking statements, as well as risks relating to
CENTOGENE’s business in general, see CENTOGENE’s risk factors set
forth in CENTOGENE’s Form 20-F filed on March 31, 2022, with the
Securities and Exchange Commission (the “SEC”) and subsequent
filings with the SEC. Any forward-looking statements contained in
this press release speak only as of the date hereof, and
CENTOGENE’s specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
Media Contact:
CENTOGENEBen Legg Corporate
Communications Press@centogene.com
Lennart StreibelInvestor RelationsIR@centogene.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Jul 2023 to Jul 2024